Sangamo BioSciences’ Platform Could Be the Future of Biotech

Sangamo BioSciences, the California-based biotech specializing in gene-modification is emerging as a leading biotech company with an innovative zinc finger platform technology. Sangamo’s diverse initiatives are profiled here, including its VEGF-A gene therapy approach currently being tested in ALS patients in a Phase II clinical trial.

Click here to read more.

Share this: